Drug intelligence / Profile preview

BMND03

Development stage: Preclinical
Lead developer: Biomind Labs
Modality: Small Molecules

Overview

BMND03 is an investigational pharmaceutical drug developed by Biomind Labs. It functions as a non-selective serotonin receptor agonist and is classified as a psychedelic hallucinogen. The drug is currently in preclinical development for the treatment of addictive disorders.

Targets

HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)

Beyond the preview

Go deeper on BMND03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMND03.